We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+14.02%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.23B
AUM Growth
+$101M
Cap. Flow
-$21.8M
Cap. Flow %
-1.78%
Top 10 Hldgs %
30.12%
Holding
96
New
14
Increased
27
Reduced
30
Closed
13

Top Buys

Rank Stock Value
1
TDOC icon
Teladoc Health
TDOC
+$23.4M
2
ABBV icon
AbbVie
ABBV
+$21.1M
3
JNJ icon
Johnson & Johnson
JNJ
+$17M
4
MRK icon
Merck
MRK
+$14.7M
5
CVS icon
CVS Health
CVS
+$11.7M

Top Sells

Rank Stock Value
1
NVCR icon
NovoCure
NVCR
+$39.6M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$25.9M
3
LVGO
Livongo Health, Inc. Common Stock
LVGO
+$23.4M
4
IMMU
Immunomedics Inc
IMMU
+$18.8M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.59%
2 Industrials 0.53%
3 Communication Services 0%
4 Consumer Discretionary 0%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
1
AbbVie
ABBV
$443B
$53.6M 4.37%
500,000
+220,000
+79% +$21.1M
BMRN icon
2
BioMarin Pharmaceuticals
BMRN
$11.6B
$44.7M 3.65%
510,000
-234,354
-31% -$18.6M
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$43.9M 3.58%
600,000
-95,000
-14% -$7.06M
MDT icon
4
Medtronic
MDT
$109B
$37.5M 3.06%
320,000
+99,220
+45% +$10.9M
UNH icon
5
UnitedHealth
UNH
$376B
$36.8M 3%
105,000
-5,000
-5% -$1.68M
JAZZ icon
6
Jazz Pharmaceuticals
JAZZ
$15.9B
$36.3M 2.96%
220,000
+50,000
+29% +$7.45M
LLY icon
7
Eli Lilly
LLY
$1.02T
$30.4M 2.48%
180,000
+15,000
+9% +$2.24M
CI icon
8
Cigna
CI
$73.7B
$29.1M 2.38%
140,000
-10,000
-7% -$1.96M
CVS icon
9
CVS Health
CVS
$133B
$28.7M 2.34%
420,000
+180,000
+75% +$11.7M
MRK icon
10
Merck
MRK
$322B
$28.1M 2.3%
360,533
+192,853
+115% +$14.7M
VRTX icon
11
Vertex Pharmaceuticals
VRTX
$121B
$27.2M 2.22%
115,000
+5,000
+5% +$1.15M
ELV icon
12
Elevance Health
ELV
$81.5B
$25.7M 2.1%
80,000
-10,000
-11% -$3.07M
HUM icon
13
Humana
HUM
$43.7B
$23.8M 1.94%
58,000
-2,000
-3% -$832K
TDOC icon
14
Teladoc Health
TDOC
$1.22B
$23M 1.88%
+115,000
New +$23.4M
AXNX
15
DELISTED
Axonics, Inc. Common Stock
AXNX
$23M 1.87%
460,000
– –
NKTR icon
16
Nektar Therapeutics
NKTR
$2.39B
$22.9M 1.87%
90,000
+23,333
+35% +$6.03M
GILD icon
17
Gilead Sciences
GILD
$162B
$22.4M 1.83%
385,000
+95,000
+33% +$5.73M
MRTX
18
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$22M 1.79%
100,000
-14,311
-13% -$3.09M
GH icon
19
Guardant Health
GH
$21.7B
$21.9M 1.79%
170,000
-70,000
-29% -$8.05M
BMY icon
20
Bristol-Myers Squibb
BMY
$133B
$21.1M 1.72%
340,000
+50,000
+17% +$3.07M
NVCR icon
21
NovoCure
NVCR
$1.73B
$20.8M 1.69%
120,000
-289,600
-71% -$39.6M
XLRN
22
DELISTED
Acceleron Pharma
XLRN
$20.5M 1.67%
160,000
+15,000
+10% +$1.76M
ABMD
23
DELISTED
Abiomed Inc
ABMD
$20.4M 1.67%
63,000
-7,000
-10% -$1.94M
BHVN
24
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$20.1M 1.64%
235,000
-75,000
-24% -$6.36M
COO icon
25
Cooper Companies
COO
$14.1B
$20M 1.63%
220,000
-20,000
-8% -$1.72M
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2020 Portfolio in Review

As of Q4 2020, Rhenman & Partners Asset Management held 96 positions worth $1.23B, up 9% from $1.12B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rhenman & Partners Asset Management's Q4 2020 filing shows 14 new, 27 increased, 30 reduced and 13 closed positions. Its largest new stake was Teladoc Health: 115,000 shares worth $23M. The largest sale was NovoCure, an estimated $39.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier, followed by Industrials and Communication Services.

  • Rhenman & Partners Asset Management's largest Q4 2020 buy was Teladoc Health: 115,000 shares worth $23M.
  • Rhenman & Partners Asset Management added most to AbbVie in Q4 2020, an estimated $21.1M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2020 reduction was NovoCure, cutting an estimated $39.6M.
  • Rhenman & Partners Asset Management fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $25.9M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 30% of its $1.23B portfolio in Q4 2020.
  • Rhenman & Partners Asset Management opened 14 new positions and closed 13 in Q4 2020.
  • Rhenman & Partners Asset Management's portfolio value rose 9% quarter-over-quarter to $1.23B.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2020, filed 19 Jan 2021.